Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
Posted innews Oncology

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combination as an additional frontline option, especially where other immunotherapy regimens are unavailable.
Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
Posted inGastroenterology news Oncology Transplantation

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI washout, and younger recipient age were independent predictors.
Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score
Posted inGastroenterology news Oncology

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful monitoring despite low PAGE-B scores.
Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes
Posted innews Oncology Radiology Specialties Superintelligence

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy.